lie for tragedieswheretherehasbeenno outreach, and previous carers may not even know about them?
nectionswith monoamineand biopterin metab olism, which we have emphasised since our earliest studiesof folate (Reynoldset a!, 1970 (Reynoldset a!, , 1984 .In a recent study of 34 patients with a DSMâ€"III diag To deal first with the design features of our methylfolate trial, we do not agree that it was inappropriate to use the Hamilton Rating Scale for Depression (HRSD) in schizophrenicpatients. The HRSD is as valid for depressionas a symptom in other psychiatric disorders as it is in depressive illness.Nor did we find the inconsistenciesbetween theHRSD and Beckscores surprising. Many of our patients were psychotic,and self-reportin such patients, many of whom are without insight, is boundto beunreliable. The objectof our studywas to evaluatelong-term (six months) clinical outcome, and the use of clinical outcome scalesin such a context iswell establishedin psychiatricresearch. We do notagreethat it isdifficultto distinguish between residual symptoms and pronounced impairment,or betweenfull socialrecoveryand no or partialsocial recovery. Theabsence of baseline scores wasdictated 
